Thursday, August 28, 2008 Free Registration Log-in to View Profiles
Empire Relations Group is a Premier Investor Relations Organization representing publicly-traded companies in their communications programs with existing shareholders and potential investors.
investments
OTCBB
OTCBB
Pressroom 
 
 Archived
 
 Non-Public Companies
 Consumer
 Energy, Environment & Natural Resources
 Financials
 Healthcare/BioTech
 Industrials
 IT & Computers
 Materials
 Telecommunications
 Utilities
 
 Public Companies
 Consumer
 Energy, Environment & Natural Resources
 Financials
 Healthcare/BioTech
 Industrials
 IT & Computers
 Materials
 Telecommunications
 Utilities
Search


Non-Public Companies : Healthcare/BioTech


Fully-Dedicated Competitive Intelligence Groups on the Rise, Cutting Edge Information Study Finds

Jul 31, 2008 - 10:36:01 AM

News Source MARKET WIRE

Email this article
 Printer friendly page
RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- 07/31/08 -- A new study released by industryleader Cutting Edge Information finds that competitive intelligencedepartments are now fully dedicated at 62% of pharmaceutical companies.The study, "Pharmaceutical Competitive Intelligence: Expanding the Role andReach of CI," finds that not only are CI departments becoming whollydedicated, but they are also taking on more strategically integrated rolesat their companies (www.pharmacompetitiveintelligence.com).

Companies of all sizes are adapting their strategies when it comes tocompetitive intelligence. Smaller companies are now beginning to formalizecompetitive intelligence activities through firmly establishedcommunication lines, if not through fully centralized departments. Thelargest companies are moving toward centralized, global-level groups thatoffer strategic value beyond the data that they collect.

According to Cutting Edge Information's research, although the CI functioncertainly has room for growth -- most departments still consist of fewerthan 10 individuals -- it is well on its way to becoming a mature,influential department.

"A decade ago, the concept of having a fully dedicated CI department was anew idea," says David Richardson, lead author of the study. "Now at manycompanies, the CI function is a fully integrated function that plays avital role in developing and executing market strategies."

The 116-page report examines CI team structures, phase-by-phase spendingand staffing, and strategies for improvement. Compiled from surveys andinterviews with executives at leading companies, the report enables CIteams to achieve success. It focuses on these topics:

--  Structuring for Success - provides details on CI structures, including    global-level reporting lines and placements; ways in which CI teams trumpet    their successes and create CI cultures; and the career paths laid out to    make CI teams breeding grounds for future pharma leaders--  Resourcing for Growth - reveals CI department-level budgets and    staffing; brand-level phase-by-phase spending and staffing; which groups    fund CI; and how companies demonstrate ROI on CI--  Increasing CI's Reach - Examines how companies communicate their    strategic value to internal clients and the resources and tools for    collecting CI    

CONTACT INFORMATION:
David Richardson
Email Contact
919-433-0216



Top of Page | Main News Index | EmpireRelations.com Home Page EmpireRelations.com Selected Clients News

Come see our services. Copr. © 2005 Empire Relations Group, Inc.

Healthcare/BioTech
Latest Headlines
Qualia Clinical Services Strengthens Financial Team
Boston Medical Center Uses Envox 7 to Pioneer a New Healthcare Delivery Model
NCSBN Inducted Its Second Group of Fellows of the NCSBN Regulatory Excellence Institute on Aug. 6, 2008, During Its Annual Meeting and Delegate Assembly
Live at Millennium Monument Park -- 2008 Olympic Athletes: Bringing a New Vision to Competition
Wolf Greenfield Wins Three More Years of Patent Protection for Shire Pharmaceuticals' ELAPRASE
New Study Finds Parents Embrace Alternative Treatments for Children's Asthma
Cutting Edge Information's Research Shows Market for Breast Cancer Drugs to Top $40 Billion by 2012
SPEEDEL SHAREHOLDERS ELECT FOUR NOVARTIS OFFICERS AS NEW MEMBERS TO THE BOARD OF DIRECTORS
Government of Canada Contributes $18-Million in Support of Red Cross Relief Efforts in China and Myanmar
TOPIGEN Pharmaceuticals Appoints Mark Parry-Billings, Ph.D., as Chief Executive Officer